Clinical Study

Mek-Nf-201- A Phase 2B Trial Of The Mek 1/2 Inhibitor (Meki) Pd-0325901 In Adult And Pediatric Patients With Neurofibromatosis Type 1 (Nf1)-Associated Inoperable Plexiform Neurofibromas (Pns) That Are Causing Significant Morbidity

Posted Date: Sep 11, 2020

  • Investigator: Soma Sengupta
  • Specialties:
  • Type of Study: Drug

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). The primary endpoint of this study is to determine Complete or partial response rate compared to baseline.


To Be Eligible: Must Have Documented Nf1 Mutation Or A Diagnosis Of Neurofibromatosis Type 1 Unresectable Plexiform Neurofibroma Causing Significant Morbidity, Adequate Organ And Bone Marrow Function, No Other Malignancy Within 5 Years, Or Breast Cancer Within 10 Years, No Abnormal Qt Interval Corrected Or Other Heart Disease Within 6 Months, No Prior Treatment With Mirdametinib (Pd-0325901) Or Any Other Mek1/2 Inhibitor, No Active Bacterial, Fungal Or Viral Infection.


Neurofibromas, Brain Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.